The osteoclast paradox in type 2 diabetes: low turnover, skeletal fragility, and implications for osteoclast-targeted therapy
- 1Department of Cadre Health Care, Peking University Shenzhen Hospital Affiliated to Shenzhen University
- 2Medical School, Shenzhen University
Abstract
Type 2 diabetes mellitus (T2DM) is increasingly recognized as a skeletal-fragility condition characterized at the population level by lower circulating markers of bone formation and resorption, frequently preserved or increased DXA-derived areal bone mineral density (aBMD), and increased fracture risk. These observations arise from different measurement levels and have not been demonstrated to constitute a single biological phenotype within the same individuals. In this Review, we use the term “osteoclast paradox” as an author-proposed heuristic framework—not a diagnostic entity or an established mechanistic syndrome—to organize apparent dissociations among circulating bone-turnover markers, osteoclast-lineage biology, tissue-level remodeling, matrix properties, and treatment response in T2DM. Direct human evidence linking these levels remains limited. A small exploratory human study suggests a possible dissociation between osteoclast precursor phenotype and mature function, whereas histomorphometry indicates that remodeling can remain coupled despite delayed progression; neither observation establishes generalized preservation or enhancement of mature osteoclast resorptive function. Experimental studies further show context-dependent effects of hyperglycemia, advanced glycation end products, oxidative stress, insulin signaling, inflammation, and the marrow environment on osteoclast differentiation and function. The observed skeletal phenotype is also modified by obesity and body composition, renal and microvascular disease, and glucose-lowering or weight-loss therapies; these overlapping exposures should not be attributed automatically to T2DM itself. Matrix glycation, altered material behavior, osteocyte dysfunction, osteoblast-lineage impairment, and altered basic multicellular unit kinetics may contribute to skeletal fragility despite low circulating turnover markers. Pooled randomized-trial analyses suggest that antiresorptive treatment responses are not obviously attenuated by T2DM, although diabetes-specific fracture estimates are unevenly powered and treatment response should not be interpreted as mechanistic validation of the proposed framework. Osteoanabolic studies demonstrate aBMD, trabecular bone score, and early microarchitectural responses, but diabetes-specific fracture endpoints remain limited. The framework is therefore intended to separate non-equivalent biological and clinical endpoints, identify evidence gaps, and generate testable hypotheses for osteoclast-targeted research. Current treatment should remain fracture risk–based rather than guided by an unvalidated turnover phenotype.
Related
- Developmental Toxicity of Tetrabromobisphenol A Bis(allyl ether) in Zebrafish: Redox Disturbance and Osteoclast-Associated Skeletal Responses.
- The complexity of skeletal fragility in overt endogenous Cushing’s syndrome: how much do we know?
- Clinical and bone-turnover outcomes associated with topical herbal plaster adjunctive therapy in older patients with myasthenia gravis and glucocorticoid-associated osteoporotic fragility fracture: a retrospective cohort study with exploratory peripheral-blood BMP-2/Smad/Runx2 analysis
- Bridging joint degeneration and systemic skeletal fragility: knee osteoarthritis as an independent risk factor for osteoporosis
- Distinct Bone Turnover Alterations Across Glycemic Phenotypes of Type 2 Diabetes and the Role of a Comprehensive Nutritional Index in Postmenopausal Women.
BibTeX
@article{jia2026osteoclast,
title = {{The osteoclast paradox in type 2 diabetes: low turnover, skeletal fragility, and implications for osteoclast-targeted therapy}},
author = {Ziang Jia and Kuan Liang and Yali Dai},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1972283},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1972283/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The osteoclast paradox in type 2 diabetes: low turnover, skeletal fragility, and implications for osteoclast-targeted therapy
AU - Ziang Jia
AU - Kuan Liang
AU - Yali Dai
PY - 2026
DA - 2026/10/30
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1972283
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1972283/full
AB - Type 2 diabetes mellitus (T2DM) is increasingly recognized as a skeletal-fragility condition characterized at the population level by lower circulating markers of bone formation and resorption, frequently preserved or increased DXA-derived areal bone mineral density (aBMD), and increased fracture risk. These observations arise from different measurement levels and have not been demonstrated to constitute a single biological phenotype within the same individuals. In this Review, we use the term “osteoclast paradox” as an author-proposed heuristic framework—not a diagnostic entity or an established mechanistic syndrome—to organize apparent dissociations among circulating bone-turnover markers, osteoclast-lineage biology, tissue-level remodeling, matrix properties, and treatment response in T2DM. Direct human evidence linking these levels remains limited. A small exploratory human study suggests a possible dissociation between osteoclast precursor phenotype and mature function, whereas histomorphometry indicates that remodeling can remain coupled despite delayed progression; neither observation establishes generalized preservation or enhancement of mature osteoclast resorptive function. Experimental studies further show context-dependent effects of hyperglycemia, advanced glycation end products, oxidative stress, insulin signaling, inflammation, and the marrow environment on osteoclast differentiation and function. The observed skeletal phenotype is also modified by obesity and body composition, renal and microvascular disease, and glucose-lowering or weight-loss therapies; these overlapping exposures should not be attributed automatically to T2DM itself. Matrix glycation, altered material behavior, osteocyte dysfunction, osteoblast-lineage impairment, and altered basic multicellular unit kinetics may contribute to skeletal fragility despite low circulating turnover markers. Pooled randomized-trial analyses suggest that antiresorptive treatment responses are not obviously attenuated by T2DM, although diabetes-specific fracture estimates are unevenly powered and treatment response should not be interpreted as mechanistic validation of the proposed framework. Osteoanabolic studies demonstrate aBMD, trabecular bone score, and early microarchitectural responses, but diabetes-specific fracture endpoints remain limited. The framework is therefore intended to separate non-equivalent biological and clinical endpoints, identify evidence gaps, and generate testable hypotheses for osteoclast-targeted research. Current treatment should remain fracture risk–based rather than guided by an unvalidated turnover phenotype.
SN - 1664-2392
ER -